Acelrx pharmaceuticals shareholder alert: former sec attorney willie briscoe and powers taylor investigate possible breaches of fiduciary duty by officers and directors

Dallas--(business wire)--former united states securities and exchange commission attorney willie briscoe, founder of the briscoe law firm, pllc, and the securities litigation firm of powers taylor llp announce that a federal class action lawsuit has been filed against acelrx pharmaceuticals, inc. (“acelrx” or “company”) (nasdaqgm: acrx) and several officers and directors for acts taken during the period of december 2, 2013 to september 25, 2014 (the “class period”). based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and board of directors of acelrx. if you are an affected acelrx shareholder and want to learn more about the lawsuit or join the action, contact willie briscoe at the briscoe law firm, pllc, (214) 239-4568, or via email at wbriscoe@thebriscoelawfirm.com, or patrick powers at powers taylor llp, toll free (877) 728-9607, or via email at shareholder@powerstaylor.com. there is no cost or fee to you. in the complaint, the defendants are alleged to have violated certain provisions of the securities exchange act of 1934. specifically, the complaint alleges that the defendants made false and or misleading statements and or failed to disclose that: a) the instructions for use (ifu) for zalviso were not designed to adequately address the risk of the inadvertent misplacement of tablets; b) the company had not submitted to the fda sufficient data to support the shelf life of the product; and c) due to the above defendants’ statements regarding zalviso were materially false and misleading at all relevant times. the briscoe law firm, pllc is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters. powers taylor llp is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.
ACRX Ratings Summary
ACRX Quant Ranking